12 Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Role of Abbott Laboratories in Global Non-Oncology Precision Medicine Market
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Agilent Technologies, Inc.
12.2.1 Company Overview
12.2.2 Role of Agilent Technologies, Inc. in Global Non-Oncology Precision Medicine Market
12.2.3 Financials
12.2.4 SWOT Analysis
12.3 Almac Group Ltd.
12.3.1 Company Overview
12.3.2 Role of Almac Group Ltd. in Global Non-Oncology Precision Medicine Market
12.3.3 SWOT Analysis
12.4 Astra Zeneca
12.4.1 Company Overview
12.4.2 Role of Astra Zeneca in Global Non-Oncology Precision Medicine Market
12.4.3 Financials
12.4.4 SWOT Analysis
12.5 ASURAGEN INC.
12.5.1 Company Overview
12.5.2 Role of ASURAGEN Inc. in Global Non-Oncology Precision Medicine Market
12.5.3 SWOT Analysis
12.6 BGI Group
12.6.1 Company Overview
12.6.2 Role of BGI Group in Global Non-Oncology Precision Medicine Market
12.6.3 SWOT Analysis
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Company Overview
12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Non-Oncology Precision Medicine Market
12.7.3 Financials
12.7.4 SWOT Analysis
12.8 bioMérieux S.A.
12.8.1 Company Overview
12.8.2 Role of bioMérieux SA. in Global Non-Oncology Precision Medicine Market
12.8.3 Financials
12.8.4 SWOT Analysis
12.9 Bristol-Myers Squibb Company
12.9.1 Company Overview
12.9.2 Role of Bristol-Myers Squibb Company in Global Non-Oncology Precision Medicine Market
12.9.3 Financials
12.9.4 SWOT Analysis
12.1 Danaher Corporation
12.10.1 Company Overview
12.10.2 Role of Danaher Corporation in Global Non-Oncology Precision Medicine Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 F. Hoffmann-La Roche Ltd
12.11.1 Company Overview
12.11.2 Role of F. Hoffman-LA Roche Ltd in Global Non-Oncology Precision Medicine Market
12.11.3 Financials
12.11.4 SWOT Analysis
12.12 Gilead Sciences, Inc.
12.12.1 Company Overview
12.12.2 Role of Gilead Sciences, Inc. in Global Non-Oncology Precision Medicine Market
12.12.3 Financials
12.12.4 SWOT Analysis
12.13 GlaxoSmithKline plc
12.13.1 Company Overview
12.13.2 Role of GlaxoSmithKline Plc in Global Non-Oncology Precision Medicine Market
12.13.3 Financials
12.13.4 SWOT Analysis
12.14 Invitae Corporation
12.14.1 Company Overview
12.14.2 Role of Invitae Corporation in Global Non-Oncology Precision Medicine Market
12.14.3 Financials
12.14.4 SWOT Analysis
12.15 Illumina, Inc.
12.15.1 Company Overview
12.15.2 Role of Illumina, Inc. in Global Non-Oncology Precision Medicine Market
12.15.3 Financials
12.15.4 SWOT Analysis
12.16 Konica Minolta, Inc.
12.16.1 Company Overview
12.16.2 Role of Konica Minolta, Inc. in Global Non-Oncology Precision Medicine Market
12.16.3 Financials
12.16.4 SWOT Analysis
12.17 Laboratory Corporation of America Holdings
12.17.1 Company Overview
12.17.2 Role of Laboratory Corporation of America Holdings in Global Non-Oncology Precision Medicine Market
12.17.3 Financials
12.17.4 SWOT Analysis
12.18 OPKO Health, Inc.
12.18.1 Company Overview
12.18.2 Role of OPKO Health, Inc. in Global Non-Oncology Precision Medicine Market
12.18.3 Financials
12.18.4 SWOT Analysis
12.19 Partek, Inc.
12.19.1 Company Overview
12.19.2 Role Partek, Inc. in Global Non-Oncology Precision Medicine Market
12.19.3 SWOT Analysis
12.2 Quest Diagnostics
12.20.1 Company Overview
12.20.2 Role of Quest Diagnostics in Global Non-Oncology Precision Medicine Market
12.20.3 Financials
12.20.4 SWOT Analysis
12.21 QIAGEN N.V.*
12.21.1 Company Overview
12.21.2 Role of QIAGEN N.V. in Global Non-Oncology Precision Medicine Market
12.21.3 Financials
12.21.4 SWOT Analysis
12.22 Randox Laboratories Ltd.
12.22.1 Company Overview
12.22.2 Role of Randox Laboratories Ltd. in Global Non-Oncology Precision Medicine Market
12.22.3 SWOT Analysis
12.23 Sanofi S.A.
12.23.1 Company Overview
12.23.2 Role of Sanofi SA in Global Non-Oncology Precision Medicine Market
12.23.3 Financials
12.23.4 SWOT Analysis
12.24 Teva Pharmaceuticals Industries Ltd.
12.24.1 Company Overview
12.24.2 Role of Teva Pharmaceuticals Industries Ltd. in Global Non-Oncology Precision Medicine Market
12.24.3 Financials
12.24.4 SWOT Analysis
12.25 Thermo Fisher Scientific Inc.
12.25.1 Company Overview
12.25.2 Role of Thermo Fisher Scientific Inc. in Global Non-Oncology Precision Medicine Market
12.25.3 Financials
12.25.4 SWOT Analysis
List of Tables
Table 4.1: Successful Non-Oncology Precision Medicine Interventions
Table 7.1: Percentage of Total Regional Aged Population (65 Years and Above: 2015 and 2030)
Table 9.1: FDA Approved Personalized Drugs Launched, Infectious Diseases, 2015-2019
Table 9.2: FDA Approved Personalized Drugs Launched, Neurology, 2015-2019
Table 9.3: FDA Approved Personalized Drugs Launched, Cardiology, 2015-2019
Table 9.4: FDA Approved Personalized Drugs Launched, Gastroenterology, 2015-2019
Table 9.5: FDA Approved Personalized Drugs Launched, Other Diseases, 2015-2019
List of Figures
Figure 1: Share of FDA Approved Non-Oncology Precision Medicine Drugs (2016-2018)
Figure 2: Global Non-Oncology Precision Medicine Market, 2019-2030
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, by Company (January 2016-August 2020)
Figure 5: Growth-Share Matrix for Global Non-Oncology Precision Medicine Market (by Company), 2019
Figure 6: Global Non-Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
Figure 7: Global Non-Oncology Precision Medicine Market (by Region)
Figure 2.1: Global Non-Oncology Precision Medicine Market Segmentation
Figure 3.1: Global Non-Oncology Precision Medicine Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Share of Total Number of Companies Profiled
Figure 4.1: Precision Medicine Model
Figure 4.2: Global Non-Oncology Precision Medicine Market, 2019-2030
Figure 4.3: Enabling Technologies of Precision Medicine
Figure 4.4: Potential of Precision Medicine
Figure 5.1: Pre-COVID-19 and Post-COVID-19 Scenario of Global Non-Oncology Precision Medicine Market, 2017-2025
Figure 5.2: Supply Chain of Non-Oncology Precision Medicine
Figure 5.3: Key Factors of Supply Chain
Figure 5.4: Measures to Bridge the Supply-Chain Gap in Non-Oncology Precision Medicine Market
Figure 6.1: Share of Patents Assigned (2015-2019)
Figure 6.2: Total Number of Patents Assigned to Key Technologies, 2016-2018
Figure 7.1: Impact Analysis of Market Dynamics
Figure 7.2: Percentage of Patients With Experience of Ineffective Drug Treatment
Figure 7.3: Steady Increase in Usage of Personalized Medicine
Figure 8.1: Share of Key Developments and Strategies, January 2016-August 2020
Figure 8.2: Share of Product Offerings, January 2016-August 2020
Figure 8.3: Share of Partnerships and Alliances, January 2016-August 2020
Figure 8.4: Share of Funding and Investment, January 2016-August 2020
Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.6: Share of Funding and Investments, January 2016-August 2020
Figure 8.7: Market Share Analysis: Global Non-Oncology Precision Medicine Market, 2019
Figure 8.8: Growth-Share Matrix for Global Non-Oncology Precision Medicine Market (by Company), 2019
Figure 9.1: Global Non-Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
Figure 9.2: Global Non-Oncology Precision Medicine Infectious Diseases Market, 2019-2030
Figure 9.3: Global on-Oncology Precision Medicine Market (for Respiratory Infections), 2019-2030
Figure 9.4: Global on-Oncology Precision Medicine Market (for Gastrointestinal Infections), 2019-2030
Figure 9.5: Global on-Oncology Precision Medicine Market (by Sexually Transmitted Infections), 2019-2030
Figure 9.6: Global on-Oncology Precision Medicine Market (for Other Infections), 2019-2030
Figure 9.7: Global Non-Oncology Precision Medicine Neurology Market, 2019-2030
Figure 9.8: Global on-Oncology Precision Medicine Market (for Neurodegenerative Disorders), 2019-2030
Figure 9.9: Global on-Oncology Precision Medicine Market (for Neuropsychiatric Disorders), 2019-2030
Figure 9.10: Global Non-Oncology Precision Medicine Market (for Other Neurology Disorders), 2019-2030
Figure 9.11: Global Non-Oncology Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
Figure 9.12: Global Non-Oncology Precision Medicine Cardiovascular Market, 2019-2030
Figure 9.13: Global on-Oncology Precision Medicine Market (for Cardiac Myopathies and Arrhythmia), 2019-2030
Figure 9.14: Global Oncology Precision Medicine Market (by Other Cardiovascular Disorder), 2019-2030
Figure 9.15: Global Non-Oncology Precision Medicine Gastroenterology Market, 2019-2030
Figure 9.16: Global Non-Oncology Precision Medicine Other Applications Market, 2019-2030
Figure 10.1: Global Non-Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
Figure 10.2: Global Non-Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
Figure 10.3: Global Non-Oncology Precision Medicine Genomics Market, 2019-2030
Figure 10.4: Global Non-Oncology Precision Medicine Genomics Market Share (by Technology)
Figure 10.5: Global Non-Oncology Precision Medicine PCR Market, 2019-2030
Figure 10.6: Global Non-Oncology Precision Medicine NGS Market, 2019-2030
Figure 10.7: Global Non-Oncology Precision Medicine Genome Editing Market, 2019-2030
Figure 10.8: Global Non-Oncology Precision Medicine Other Technologies Market, 2019-2030
Figure 10.9: Global Non-Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
Figure 10.10: Global Non-Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
Figure 10.11: Global Non-Oncology Precision Medicine Market (by Precision Diagnostics)
Figure 10.12: Global Non-Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
Figure 10.13: Global Non-Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
Figure 10.14: Global Non-Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
Figure 10.15: Global Non-Oncology Precision Medicine Medical Imaging Market, 2019-2030
Figure 10.16: Global Non-Oncology Precision Medicine Digital Health and Information Technology Market,2019-2030
Figure 10.17: Global Non-Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
Figure 10.18: Global Non-Oncology Precision Medicine CDSS Market, 2019-2030
Figure 10.19: Global Non-Oncology Precision Medicine Big Data Analytics Market, 2019-2030
Figure 10.20: Global Non-Oncology Precision Medicine IT Infrastructure Market, 2019-2030
Figure 10.21: Global Non-Oncology Precision Medicine Genomics Informatics Market, 2019-2030
Figure 10.22: Global Non-Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
Figure 10.23: Global Non-Oncology Precision Medicine Mobile Health Market, 2019-2030
Figure 10.24: Global Non-Oncology Precision Medicine Therapeutics Market, 2019-2030
Figure 10.25: Global Non-Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
Figure 10.26: Global Non-Oncology Precision Medicine Clinical Trials Market, 2019-2030
Figure 10.27: Global Non-Oncology Precision Medicine Cell Therapy Market, 2019-2030
Figure 10.28: Global Non-Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
Figure 10.29: Global Non-Oncology Precision Medicine Gene Therapy Market, 2019-2030
Figure 11.1: Global Non-Oncology Precision Medicine Market (by Region)
Figure 11.2: North America Global Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America Global Non-Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.5: U.S. Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.6: Canada Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.7: Europe Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe Non-Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.10: Germany Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.11: France Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.12: Italy Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.13: The U.K. Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.14: Spain Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.15: Rest-of-Europe Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.16: Asia-Pacific Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.17: Asia-Pacific: Market Dynamics
Figure 11.18: Asia-Pacific Non-Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.19: China Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.20: Japan Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.21: Australia Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.22: India Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.23: Rest-of-Asia-Pacific Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.24: Latin America Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.25: Latin America: Market Dynamics
Figure 11.26: Latin America Global Non-Oncology Precision Medicine Market (by Country), 2019 and 2030
Figure 11.27: Brazil Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.28: Mexico Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.29: Mexico Non-Oncology Precision Medicine Market, 2019-2030
Figure 11.30: Rest-of-the-World Non-Oncology Precision Medicine Market, 2019-2030
Figure 12.1: Abbott Laboratories.: Overall Product Offerings
Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
Figure 12.6: Abbott Laboratories: SWOT Analysis
Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.13: Almac Group Ltd.: Overall Product Offerings
Figure 12.14: Almac Group Ltd.: SWOT Analysis
Figure 12.15: Astra Zeneca: Overall Product Portfolio
Figure 12.16: Astra Zeneca: Overall Financials, 2017-2019
Figure 12.17: Astra Zeneca: Revenue (by Business Segment), 2017-2019
Figure 12.18: Astra Zeneca: Revenue (by Region), 2017-2019
Figure 12.19: Astra Zeneca: SWOT Analysis
Figure 12.20: ASURAGEN, INC.: Overall Product Offerings
Figure 12.21: ASURAGEN INC.: SWOT Analysis
Figure 12.22: BGI Group.: Overall Product Portfolio
Figure 12.23: BGI Group: SWOT Analysis
Figure 12.24: Bio-Rad Laboratories, Inc: Overall Product Offerings
Figure 12.25: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
Figure 12.27: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
Figure 12.28: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
Figure 12.29: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.30: bioMérieux S.A.: Overall Product Portfolio
Figure 12.31: bioMérieux S.A.: Overall Financials, 2017-2019
Figure 12.32: bioMérieux S.A.: Revenue (by Segment), 2017-2019
Figure 12.33: bioMérieux S.A.: Revenue (by Region), 2018 and 2019
Figure 12.34: bioMérieux S.A.: SWOT Analysis
Figure 12.35: Bristol-Myers Squibb Company: Overall Product Portfolio
Figure 12.36: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
Figure 12.37: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
Figure 12.38: Bristol-Myers Squibb Company: SWOT Analysis
Figure 12.39: Danaher Corporation: Overall Product Portfolio
Figure 12.40: Danaher Corporation: Overall Financials, 2017-2019
Figure 12.41: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.42: Danaher Corporation: SWOT Analysis
Figure 12.43: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 12.44: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 12.45: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 12.46: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 12.47: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 12.48: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 12.49: Gilead Sciences, Inc.: Overall Product Portfolio
Figure 12.50: Gilead Sciences, Inc.: Overall Financials, 2017-2019
Figure 12.51: Gilead Sciences, Inc. : R&D Expenditure, 2017-2019
Figure 12.52: Gilead Science, Inc.: SWOT Analysis
Figure 12.53: GlaxoSmithKline Plc.: Overall Product Portfolio
Figure 12.54: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 12.55: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 12.56: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 12.57: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 12.58: GlaxoSmithKline plc: SWOT Analysis
Figure 12.59: Invitae Corporation: Overall Product Portfolio
Figure 12.60: Invitae Corporation: Overall Financials, 2017-2019
Figure 12.61: Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 12.62: Invitae Corporation: Revenue (by Region), 2017-2019
Figure 12.63: Invitae Corporation: R&D Expenditure, 2017-2019
Figure 12.64: Invitae Corporation: SWOT Analysis
Figure 12.65: Illumina, Inc.: Overall Product Portfolio
Figure 12.66: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.67: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.68: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.69: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Illumina, Inc.: SWOT Analysis
Figure 12.71: Konica Minolta, Inc.: Overall Product Portfolio
Figure 12.72: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 12.73: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
Figure 12.74: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
Figure 12.75: Konica Minolta, Inc.: SWOT Analysis
Figure 12.76: Laboratory Corporation of America Holdings.: Overall Product Portfolio
Figure 12.77: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 12.78: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 12.79: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 12.80: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 12.81: OPKO Health, Inc.: Overall Product Portfolio
Figure 12.82: OPKO Health, Inc.: Overall Financials, 2017-2019
Figure 12.83: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
Figure 12.84: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.85: OPKO Health, Inc.: Research and Development Expense, 2017-2019
Figure 12.86: OPKO Health, Inc.: SWOT Analysis
Figure 12.87: Partek, Inc: Overall Product Portfolio
Figure 12.88: Partek, Inc.: SWOT Analysis
Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 12.98: QIAGEN N.V.: SWOT Analysis
Figure 12.99: Randox Laboratories Ltd.: SWOT Analysis
Figure 12.100: Sanofi SA: Overall Product Portfolio
Figure 12.101: Sanofi SA: Overall Financials, 2017-2019
Figure 12.102: Sanofi SA: Revenue (by Segment), 2017-2019
Figure 12.103: Sanofi SA: Revenue (by Region), 2017-2019
Figure 12.104: Sanofi SA: R&D Expenditure, 2017-2019
Figure 12.105: Sanofi SA: SWOT Analysis
Figure 12.106: Teva Pharmaceuticals Industries Ltd.: Overall Product Portfolio
Figure 12.107: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
Figure 12.108: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
Figure 12.109: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
Figure 12.110: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
Figure 12.111: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.112: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 12.113: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 12.114: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 12.115: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 12.116: Thermo Fisher Scientific Inc.: SWOT Analysis